U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C24H20ClFN4O4
Molecular Weight 482.891
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE

SMILES

OCC(O)C(=O)NC1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1

InChI

InChIKey=NWFMVILQVXZATJ-UHFFFAOYSA-N
InChI=1S/C24H20ClFN4O4/c25-19-10-17(5-7-22(19)34-12-14-2-1-3-15(26)8-14)29-23-18-9-16(30-24(33)21(32)11-31)4-6-20(18)27-13-28-23/h1-10,13,21,31-32H,11-12H2,(H,30,33)(H,27,28,29)

HIDE SMILES / InChI

Molecular Formula C24H20ClFN4O4
Molecular Weight 482.891
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 16:11:15 GMT 2023
Edited
by admin
on Sat Dec 16 16:11:15 GMT 2023
Record UNII
GGA6DL772Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE
Systematic Name English
ALLITINIB METABOLITE M10
Common Name English
PROPANAMIDE, N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXY-
Systematic Name English
Code System Code Type Description
CAS
1469980-18-4
Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023
PRIMARY
PUBCHEM
156028094
Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023
PRIMARY
FDA UNII
GGA6DL772Q
Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET->WEAK INHIBITOR
IC50
Related Record Type Details
PARENT -> METABOLITE
FECAL; PLASMA; URINE
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC IN CANCER PATIENTS

THREE TIMES A DAY FOR 21 DAYS

ORAL ADMINISTRATION

AT DAY 24

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

AT DAY 1

THREE TIMES A DAY

IN CANCER PATIENTS

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

THREE TIMES A DAY FOR 21 DAYS

AT DAY 24

IN CANCER PATIENTS

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

IN CANCER PATIENTS

THREE TIMES A DAY

AT DAY 1